18/12/2025
Did you know that most clinical trials don’t reflect the diversity of communities they’re meant to help?
In the US, 84% of clinical trial participants are white, and globally, most studies take place in the US and Europe, leaving many regions and communities underrepresented.
The diversity gap shows up clearly in clinical trials related to psoriasis research:
✔️In the United States, white people make up around 57.5% of the population, yet psoriasis clinical trials do not reflect this diversity. Only 30% of trials included more than 20% non-white participants, meaning that in the majority of trials, non-white communities were minimally represented or not represented at all.
✔️In phase III trials for plaque psoriasis, which guide treatment decisions, just 14.2% of participants were non-white.
These numbers highlight a serious problem: when clinical research isn’t diverse, it can lead to serious gaps in understanding of the disease and access to care, slowing progress and widening health inequalities.
That’s why IFPA launched Breaking Barriers in Psoriatic Disease — a global initiative to identify the obstacles that prevent people from participating in psoriasis research.
Working together with world-class experts, the project team explores how stigma, culture, geography, and socioeconomic factors affect participation — and develops practical tools to foster inclusion and equity in research.
Breaking Barriers aims to ensure every voice is represented in psoriatic disease research. Make your voice heard, share your experience with us.
Read more: https://eu1.hubs.ly/H0qxyTJ0
